The Week’s 10 Biggest Funding Rounds: $400M For Neurotech Leads, Followed By Big Deals For AI, Fintech, Biotech And More

The venture capital landscape experienced a paradoxical week between November 14 and November 20, 2026. While the public markets grappled with significant downward pressure and broad volatility in the tech sector, private markets demonstrated remarkable resilience. This divergence underscores a sustained appetite among institutional investors for high-growth, transformative technologies, even as the shadow of a public market correction looms over long-term exit strategies.
The week was anchored by a major milestone in the tech ecosystem: Anthropic successfully executed its initial public offering. This event served as a litmus test for AI-centric startups, signaling that despite current market turbulence, there remains a path to liquidity for industry leaders. However, the subsequent decline in tech stocks has raised alarms among analysts, who suggest that if current negative sentiment persists, the "valuation gap" between private and public companies could widen, potentially cooling down late-stage dealmaking in the coming quarters.
A Strong Showing for Deep Tech and Biotech
Despite the atmospheric uncertainty, capital continued to flow into sectors characterized by high R&D intensity. Leading the U.S. domestic funding activity was Science, a neurotech company, which secured $400 million in Series D financing. On the international front, the United Kingdom-based AI biotech firm Isomorphic Labs captured global headlines by securing an eye-watering $5 billion in funding, proving that the synergy between generative AI and life sciences remains the primary target for massive capital deployments.
Analysis of the Top 10 U.S. Funding Rounds
-
Science ($400M, Neurotech): Based in Alameda, California, Science continues to push the boundaries of neural engineering. This $400 million round, which brings the company’s total cumulative funding to over $900 million, highlights the increasing investor confidence in brain-computer interface (BCI) technology. As the company moves deeper into clinical development, the capital will likely be utilized to scale its infrastructure and accelerate human trials.
-
Model ML ($250M, AI/Fintech): In a move that signals the maturation of enterprise AI, Model ML closed a $250 million Series B at a $1.5 billion valuation. Led by General Atlantic and QED Investors, the round highlights a shift from "general-purpose AI" to industry-specific, high-stakes applications. By focusing on financial and professional services, Model ML is positioning itself as an essential layer in the modernization of legacy institutional workflows.
-
Galvanize Therapeutics ($130M, Biotech): Redwood City-based Galvanize Therapeutics secured $130 million in Series D funding. The company, which specializes in pulsed electric field (PEF) ablation for oncology and chronic diseases, is operating in a high-growth niche of medical technology. The involvement of HealthQuest Capital reflects the growing interest in non-invasive, device-led therapeutic solutions that can be integrated into existing clinical settings.
-
General Flash ($128M, Critical Metals): Addressing the supply chain bottleneck for essential minerals, General Flash raised $128 million across seed and Series A rounds. As the global energy transition places unprecedented demand on rare earth metals and critical battery components, startups that provide proprietary, scalable production methods are attracting significant interest from infrastructure-focused venture funds.
-
Ramon.Space ($124M, Space Tech): The commercialization of space continues to be a frontier for venture capital. Denver-based Ramon.Space secured $124 million in Series B funding to advance its space-computing infrastructure. By enabling high-performance processing in orbit, the company is attempting to solve the data-latency challenges that have historically hampered satellite operations and deep-space research.
-
Marrow Therapeutics ($120M, Biotech): Launching with an impressive total of $173 million—comprising a $120 million Series B and a $53 million Series A—Marrow Therapeutics enters the market with significant momentum. The Watertown, Massachusetts-based firm is targeting severe blood disorders through bone marrow-targeted therapies, a specialized field that continues to attract elite life-science venture firms like Orbimed and Scion Life Sciences.
-
Noeri ($110M, Enterprise AI): Founded by esteemed Stanford University computer science faculty, Noeri emerged with $110 million in initial capital. The company focuses on self-improving AI, a development that suggests the next wave of enterprise software will be less reliant on human-in-the-loop fine-tuning and more capable of autonomous iteration. Menlo Ventures’ lead position suggests a long-term commitment to this architectural evolution.
-
Seawolf Therapeutics ($100M, Biotech): Emerging from stealth with a $100 million war chest, this San Diego biotech is developing a novel DNA delivery platform. The backing of high-profile entities such as Versant Ventures and Novartis Venture Fund underscores the commercial viability of next-generation genetic delivery systems in the pharmaceutical space.
-
BrightAI ($97M, Physical AI): BrightAI is bridging the gap between digital intelligence and industrial operations. By deploying sensors, drones, and robotics, the Silicon Valley startup aims to provide "continuous observability" to the power and water sectors. This move highlights a broader trend: the integration of AI into the physical, heavy-industry backbone of the global economy.
-
Vincue ($93M, Vehicle Intelligence): Closing out the top ten, Kansas City-based Vincue secured $93 million in growth capital. The company’s focus on vehicle lifecycle intelligence for the automotive sector points to a growing demand for data-driven precision in inventory management and fleet optimization.
Broader Market Implications
The funding activity for the week of November 14-20, 2026, reveals a distinct bifurcated market. On one hand, "Deep Tech"—comprising neurotech, space computing, and advanced biotech—continues to draw large-scale, long-horizon investment. These companies are viewed as "moated" assets, insulated from the immediate whims of the stock market by their proprietary R&D and long-term regulatory pathways.
Conversely, the fintech and enterprise AI sectors are beginning to feel the pressure of the wider economic climate. While rounds like Model ML’s $250 million infusion are impressive, the valuation of $1.5 billion reflects a cautious market that is rewarding proven revenue and specific vertical integration rather than the "growth at all costs" mentality seen in previous years.
The Looming Shadow of Public Markets
The recent volatility in tech stocks acts as a gravitational force on private markets. If the IPO window—opened by Anthropic—starts to narrow due to weak performance in secondary trading, venture firms will likely pivot to a more defensive strategy. This would mean longer due diligence cycles, a higher emphasis on profitability over top-line growth, and a potential decrease in the frequency of "megadeals" (rounds exceeding $100 million).
However, current data from the Crunchbase Megadeals Board suggests that capital remains abundant for those who can prove their technology provides a tangible efficiency gain or solves a critical bottleneck in the physical or digital economy. Investors are currently prioritizing "infrastructure"—whether it is space computing, neurotech platforms, or AI-driven industrial observability—over speculative consumer-facing applications.
Looking Ahead
As we head toward the close of 2026, the primary metric for success will not just be the size of the funding round, but the efficiency of capital deployment. The $5 billion raised by Isomorphic Labs and the $400 million raised by Science represent a specific type of investment: high-risk, high-reward ventures that are essential for long-term technological progress. For the rest of the ecosystem, the message from the past week is clear: while the doors to private capital remain open, the requirements for entry are becoming increasingly stringent, favoring companies that can demonstrate both technical mastery and a clear, defensible business model in an increasingly skeptical economic environment.







